I thought that EXEL was getting a little ahead of itself at $8, but I'm not one to complain. It's gone up and down quite a bit over the years and I've bought on a couple of the dips, including the last drop below $6 a month ago. Yes, there is great potential here and it seems like while there are no drugs close to being released to market, EXEL has built great relationships and is working collaboratively with the big dogs. Things should get interesting in 2-5 years when the pipeline has matured and EXEL's research finally pays off. Investors and patients both win.Cheers to the eradication of cancer.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat